Type 2 Diabetes
Conditions
Keywords
Type 2 diabetes, Closed-loop strategy, Artificial pancreas, Insulin, Elderly, Multiple daily injections, Hypoglycemia
Brief summary
The introduction of insulin pump therapy in patients with type 2 diabetes using multiple daily injections and poorly controlled can be considered in order to improve glycemic control. Recent developments of continuous glucose sensors and insulin infusion pumps have motivated the research toward closed-loop'' strategies to regulate glucose levels for patients with diabetes. In a closed-loop strategy, the pump(s) infusion rate is altered based on a computer generated recommendation that rely on continuous glucose sensor readings. This study confirmed the feasibility and potential of the closed-loop strategy to improve glycemic control while reducing the risk of hypoglycemia in patients with type 2 diabetes but did not target the population most likely to benefit from this strategy.The objective ot this study is to compare the efficacy of closed-loop strategy to multiple daily injections in regulating glucose levels for 24 hours in elderly adults with type 2 diabetes under intensive insulin therapy. The investigators hypothesize that closed-loop strategy will increase the time spent in the target range in adults with type 2 diabetes compared to multiple daily injections.
Interventions
OTHER24-hour intervention with multiple daily injections
Subjects will be admitted at the research clinical facility at 20:00. A cannula will be inserted into an arm or a hand vein for blood sampling purposes. The subjects will carry on with their normal insulin therapy. Two periods of walking of 15 minutes will be performed at 10:00 and 15:00. Meals will be served at 8:00, 12:00 and 17:00. The CHO content of meals will be adapted to subject's usual CHO intake. Venous blood samples (4 ml each) will be obtained for the measurement of the plasma glucose and insulin. Plasma glucagon and C-peptide will be measured every hour. Blood samples will be drawn every 20 minutes.
OTHER24-hour intervention with closed-loop strategy
Subjects will be admitted at the research clinical facility at 20:00. A cannula will be inserted into an arm or a hand vein for blood sampling purposes. A cartridge containing subject's usual fast acting insulin analog will be placed in the insulin pump. Closed-loop strategy will start at 21:00 until 21:00 the next day. Neither basal nor prandial insulin injections will be given. Two periods of walking of 15 minutes will be performed at 10:00 and 15:00. Meals will be served at 8:00, 12:00 and 17:00. The CHO content of meals will be adapted to subject's usual CHO intake. Venous blood samples (4 ml each) will be obtained for the measurement of the plasma glucose and insulin. Plasma glucagon and C-peptide will be measured every hour. Blood samples will be drawn every 20 minutes.
DRUGInsulin
Subject's usual insulin analog will be used.
DEVICEInsulin pump Accu-Chek Combo
During closed-loop intervention, the Accu-Chek Combo (Roche) insulin pump will be used
DEVICEDexcom G4 Platinum
In both visits, glucose levels will be measure with the Dexcom G4 Platinum (Dexcom)
Sponsors
Réseau de recherche en santé cardiométabolique, diabète et obésité
Institut de Recherches Cliniques de Montreal
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
55 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Type 2 diabetes. 2. Males and females ≥ 55 years of old. 3. Body mass index above 25 kg/m2 4. Non fragile defined based on Moorhouse et al. scale \[23\]. 5. Using at least 3 insulin injections per day. However, basal insulin injection must be injected at bedtime without injection of basal insulin in the morning. Combination with any other anti-diabetic therapy is acceptable as long at this therapy was introduced at least 6 weeks prior the 1s intervention and is kept stable all along the protocol. 6. HbA1c above 6%.
Exclusion criteria
1. Advanced 1. Nephropathy defined by creatinine clearance \<30 ml/min. 2. Retinopathy as proliferative retinopathy or recent (\<3 month) eye bleeding or laser therapy. If the patient have undergone panphoto-coagulation inclusion is acceptable. 3. Autonomic neuropathy with clinically significant gastroparesis according to investigator evaluation. 2. Recent (\< 6 months) acute macrovascular event e.g. acute coronary syndrome or cardiac surgery. 3. A recent (\< 2 months) injury to body or limb, muscular disorder, use of any medication or other significant medical disorder if that injury, medication or disease in the judgment of the investigator will affect the ability to walk. 4. A recent (\< 2 months) infection needing IV antibiotic or hospitalization 5. Severe hypoglycemic episode within two weeks of screening. 6. Current use of glucocorticoid medication (by any route of administration except low dose stable inhaled). 7. Recent initiation or dose modification (\<2 months) of therapy known to interfere with glucose metabolism (e.g. neuroleptics, anti-psychotics, etc.) 8. Known or suspected allergy to the trial products or meal contents. 9. Other serious medical illness likely to interfere with study participation or with the ability to complete the trial by the judgment of the investigator.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of time of plasma glucose concentrations spent in the target range | 24 hours | The target range is defined as between 4.0 and 10.0 mmol/L 2-hour postprandial and between 4.0 to 8.0 mmol/L otherwise. |
Secondary
| Measure | Time frame |
|---|---|
| Percentage of time of plasma glucose levels spent below 4.0 mmol/L | 24 hours |
| Percentage of time of plasma glucose levels spent below 3.5 mmol/L | 24 hours |
| Percentage of time of plasma glucose levels spent above 8.0 mmol/L | 24 hours |
| Percentage of time of plasma glucose levels spent above 10.0 mmol/L | 24 hours |
| Percentage of time of overnight plasma glucose levels spent below 4.0 mmol/L | 8 hours |
| Percentage of time of overnight plasma glucose levels spent between 4.0 and 8.0 mmol/L | 8 hours |
| Percentage of time of overnight plasma glucose levels spent between 4.0 and 10.0 mmol/L | 8 hours |
| Percentage of time of overnight plasma glucose levels spent below 3.5 mmol/L | 8 hours |
| Percentage of time of overnight plasma glucose levels above 8.0 mmol/L | 8 hours |
| Percentage of time of overnight plasma glucose levels above 10.0 mmol/L | 8 hours |
| Area under the curve of plasma glucose levels below 4.0 mmol/L | 24 hours |
| Percentage of time of plasma glucose levels spent between 4.0 to 10.0 mmol/L | 24 hours |
| Area under the curve of plasma glucose levels above 8.0 mmol/L | 24 hours |
| Area under the curve of plasma glucose levels above 10.0 mmol/L | 24 hours |
| Area under the curve of overnight plasma glucose levels below 4.0 mmol/L | 8 hours |
| Area under the curve of overnight plasma glucose levels below 3.5 mmol/L | 8 hours |
| Area under the curve of overnight plasma glucose levels above 8.0 mmol/L | 8 hours |
| Area under the curve of overnight plasma glucose levels above 10.0 mmol/L | 8 hours |
| Mean glucose levels | 24 hours |
| Total insulin delivery | 24 hours |
| Standard deviation of plasma glucose concentrations | 24 hours |
| Coefficient of variance of plasma glucose concentrations | 24 hours |
| Number of patients experiencing at least one hypoglycemic event requiring treatment | 24 hours |
| Area under the curve of plasma glucose levels below 3.5 mmol/L | 24 hours |
Countries
Canada
Outcome results
None listed